基因沉默市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球基因沉默市场规模达96亿美元，预计到2034年将以11.6%的复合年增长率增长，达到285亿美元，这得益于全球遗传病发病率的上升以及对下一代疗法日益增长的需求。随着越来越多的人被诊断出患有遗传性疾病，人们对修改或抑制致病基因的治疗方法的兴趣也日益浓厚。医疗保健系统正致力于精准医疗，而基因沉默在这一转变中发挥着至关重要的作用，它能够提供传统药物无法实现的精准治疗效果。随着生物技术工具的改进和临床研发管线的不断完善，基于基因的干预措施正迅速受到研究人员和医疗服务提供者的青睐。

该市场见证了令人瞩目的技术进步，尤其是在先进基因调控方法的应用方面。 2024年，该产品领域的规模达到77亿美元，预计未来将持续成长。 CRISPR-Cas9、反义寡核苷酸 (ASO) 和RNA干扰 (RNAi) 等工具已被证明在分子层面上治疗遗传疾病方面至关重要。这些技术正在为标靶治疗开闢新的机会，ASO 在罕见疾病管理中展现出良好的前景，而RNAi 则逐渐成为更广泛治疗应用的平台。

由于RNAi及相关技术在研究中的应用日益广泛，因此药物研发领域的基因沉默市场在2024年占了51%的份额。製药和生物技术公司正在利用这些工具来精确定位致病基因，并简化药物开发的早期阶段。随着新型疗法临床试验在不同治疗领域的扩展，对基因标靶平台的需求持续成长。

预计2034年，美国基因沉默市场规模将达111亿美元。美国拥有强大的科学研究基础设施，并在赛默飞世尔科技、安捷伦科技和Bio-Rad Laboratories等领先公司的支持下，为基因沉默治疗的持续创新提供了支持。持续的研发投入和监管支持也创造了良好的成长环境。美国仍然是基因组医学临床进展和资金支持的中心。

默克集团 (Merck KGaA)、金斯瑞 (GenScript)、Revvity Discovery、圣克鲁斯生物技术公司 (Santa Cruz Biotechnology) 和新英格兰生物实验室 (New England Biolabs) 等主要参与者正透过重点投资 RNAi 和 ASO 平台来巩固其市场地位。这些公司正在透过基因编辑工具、客製化寡核苷酸合成和可扩展的递送系统扩展其产品组合。与学术机构和生物技术新创公司建立的策略合作伙伴关係有助于他们在临床创新领域保持领先地位。各公司投资于自动化、基于人工智慧的基因标靶筛选和增强的实验室基础设施，以加快研究週期。持续努力获得监管部门的批准并开发伴随诊断产品也是保持竞争力的关键。透过将产品创新与精准治疗趋势相结合，这些公司充分利用了市场对标靶基因治疗日益增长的需求。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 遗传性疾病盛行率上升
    • 增加对标靶治疗的需求
    • 交付系统的进步
    • 生物技术和製药研究的投资不断增加
  • 产业陷阱与挑战
    • 严格的监管准则
    • 成本高、技术复杂
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 各国应对措施
  • 对产业的影响
    • 供应方影响（製造成本）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（消费者成本）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 技术格局
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按类型，2021 年至 2034 年

• 主要趋势
• 产品
  • RNA干扰
    • miRNA
    • siRNA
    • 其他RNAi产品
  • CRISPR-Cas9
    • CRISPR 试剂盒和试剂
    • CRISPR文库
    • 其他 CRISPR-CAS 9 产品
  • 反义寡核苷酸（ASO）
  • 其他产品
• 服务

第六章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 药物发现与开发
  • 神经病学
  • 肿瘤学
  • 传染病
  • 遗传性疾病
  • 其他药物发现和发展
• 治疗药物製造
• 农业应用
• 其他应用

第七章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 製药和生物技术公司
• 学术和研究机构
• CRO 和 CMO
• 其他最终用途

第八章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋

第九章：公司简介

• Agilent Technologies
• Bio-Rad Laboratories
• Cellecta
• Danaher
• GenScript
• Merck KGaA
• New England Biolabs
• Qiagen
• Revvity Discovery
• Santa Cruz Botechnology
• Thermo Fisher Scientific

The Global Gene Silencing Market was valued at USD 9.6 billion in 2024 and is estimated to grow at a CAGR of 11.6% to reach USD 28.5 billion by 2034, driven by a rising global incidence of genetic diseases and rising demand for next-generation therapies. As more individuals are diagnosed with inherited conditions, the interest in treatments that modify or suppress disease-causing genes has accelerated. Healthcare systems are focusing on precision medicine, and gene silencing plays a crucial role in this shift, offering targeted therapeutic outcomes that conventional drugs cannot achieve. With improved biotechnological tools and stronger clinical pipelines, gene-based interventions are rapidly gaining traction among researchers and care providers.

The market has witnessed impressive technological strides, particularly with the adoption of advanced gene regulation methods. In 2024, the products segment held USD 7.7 billion, with continued expansion expected. Tools like CRISPR-Cas9, antisense oligonucleotides (ASOs), and RNA interference (RNAi) have proven vital in addressing genetic disorders at the molecular level. These technologies are unlocking new opportunities for targeted treatment, with ASOs showing promise in rare disease management and RNAi emerging as a platform for broader therapeutic applications.

Gene silencing market from the drug discovery and development segment captured 51% share in 2024 due to the growing use of RNAi and related technologies in research. Pharmaceutical and biotech companies are utilizing these tools to pinpoint disease-causing genes and streamline the early phases of drug development. The demand for gene-targeting platforms continues to grow as clinical trials for novel therapeutics expand across different therapeutic areas.

United States Gene Silencing Market is expected to reach USD 11.1 billion by 2034. The country's robust research infrastructure, backed by leading firms such as Thermo Fisher Scientific, Agilent Technologies, and Bio-Rad Laboratories, supports steady innovation in gene silencing treatments. Ongoing R&D investment and regulatory support also contribute to a favorable growth environment. The country remains a hub for clinical advancements and funding in genomic medicine.

Key players such as Merck KGaA, GenScript, Revvity Discovery, Santa Cruz Biotechnology, and New England Biolabs are strengthening their market presence through focused investments in RNAi and ASO platforms. These companies are expanding their portfolios with gene editing tools, custom oligo synthesis, and scalable delivery systems. Strategic partnerships with academic institutions and biotech startups help them stay ahead in clinical innovation. Firms invest in automation, AI-based gene target screening, and enhanced laboratory infrastructure to speed up research cycles. Continuous efforts to secure regulatory approvals and develop companion diagnostics are also central to competitiveness. By aligning product innovation with precision therapy trends, these companies capitalize on the growing need for targeted genetic treatments.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of genetic disorders
    • 3.2.1.2 Increase demand for targeted therapies
    • 3.2.1.3 Advancements in delivery systems
    • 3.2.1.4 Growing investment in biotech and pharmaceutical research
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory guidelines
    • 3.2.2.2 High cost and technical complexity
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Country-wise response
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (Cost of manufacturing)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (Cost to consumers)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Product
  • 5.2.1 RNAi
    • 5.2.1.1 miRNA
    • 5.2.1.2 siRNA
    • 5.2.1.3 Other RNAi products
  • 5.2.2 CRISPR-Cas9
    • 5.2.2.1 CRISPR kits and reagents
    • 5.2.2.2 CRISPR libraries
    • 5.2.2.3 Other CRISPR-CAS 9 products
  • 5.2.3 Antisense oligonucleotides (ASOs)
  • 5.2.4 Other products
• 5.3 Services

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drug discovery and development
  • 6.2.1 Neurology
  • 6.2.2 Oncology
  • 6.2.3 Infectious diseases
  • 6.2.4 Genetic disorders
  • 6.2.5 Other drug discoveries and developments
• 6.3 Therapeutics manufacturing
• 6.4 Agricultural applications
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical and biotechnology companies
• 7.3 Academic and research institutes
• 7.4 CROs and CMOs
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Agilent Technologies
• 9.2 Bio-Rad Laboratories
• 9.3 Cellecta
• 9.4 Danaher
• 9.5 GenScript
• 9.6 Merck KGaA
• 9.7 New England Biolabs
• 9.8 Qiagen
• 9.9 Revvity Discovery
• 9.10 Santa Cruz Botechnology
• 9.11 Thermo Fisher Scientific